- Home
- CHH vs JAZZ Comparison
CHH vs JAZZ Comparison
Compare CHH & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHH
- JAZZ
- Stock Information
- Founded
- CHH 1939
- JAZZ 2003
- Country
- CHH United States
- JAZZ Ireland
- Employees
- CHH N/A
- JAZZ N/A
- Industry
- CHH Hotels/Resorts
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CHH Consumer Discretionary
- JAZZ Health Care
- Exchange
- CHH Nasdaq
- JAZZ Nasdaq
- Market Cap
- CHH 5.8B
- JAZZ 6.7B
- IPO Year
- CHH 1997
- JAZZ 2007
- Fundamental
- Price
- CHH $122.88
- JAZZ $107.51
- Analyst Decision
- CHH Hold
- JAZZ Strong Buy
- Analyst Count
- CHH 14
- JAZZ 12
- Target Price
- CHH $133.64
- JAZZ $183.08
- AVG Volume (30 Days)
- CHH 402.3K
- JAZZ 730.8K
- Earning Date
- CHH 08-07-2025
- JAZZ 07-30-2025
- Dividend Yield
- CHH 0.94%
- JAZZ N/A
- EPS Growth
- CHH 40.19
- JAZZ 49.21
- EPS
- CHH 6.57
- JAZZ 7.51
- Revenue
- CHH $797,663,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- CHH $103.49
- JAZZ $6.05
- Revenue Next Year
- CHH $3.35
- JAZZ $4.68
- P/E Ratio
- CHH $18.54
- JAZZ $14.35
- Revenue Growth
- CHH N/A
- JAZZ 5.76
- 52 Week Low
- CHH $116.13
- JAZZ $95.49
- 52 Week High
- CHH $157.86
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- CHH 41.14
- JAZZ 45.65
- Support Level
- CHH $121.42
- JAZZ $106.56
- Resistance Level
- CHH $131.40
- JAZZ $109.43
- Average True Range (ATR)
- CHH 2.82
- JAZZ 2.66
- MACD
- CHH -0.57
- JAZZ -0.16
- Stochastic Oscillator
- CHH 15.14
- JAZZ 12.27
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represent 78% of total rooms in 2024.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.